Dunvegan Associates’s Novo Nordisk NVO Stock Holding History

Dunvegan Associates’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$1.47M	Sell	50,454 -1,100	-2%	-$30.4K	1.72%	16
2015 Q3	$1.4M	Sell	51,554 -750	-1%	-$21.2K	1.59%	19
2015 Q2	$1.43M	Sell	52,304 -15,700	-23%	-$441K	1.58%	20
2015 Q1	$1.81M	Sell	68,004 -150	-0.2%	-$3.45K	1.61%	21
2014 Q4	$1.44M	Sell	68,154 -1,082	-2%	-$24.2K	1.25%	22
2014 Q3	$1.65M	Buy	69,236 +266	+0.4%	+$6.12K	1.49%	21
2014 Q2	$1.59M	Hold	68,970	–	–	1.33%	23
2014 Q1	$1.57M	Sell	68,970 -59,460	-46%	-$1.27M	1.32%	27
2013 Q4	$2.37M	Sell	128,430 -6,050	-4%	-$105K	1.96%	17
2013 Q3	$2.28M	Sell	134,480 -3,710	-3%	-$62.4K	1.68%	23
2013 Q2	$2.14M	Buy	+138,190	New	+$2.3M	1.65%	22

Other funds holding NVO

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Dunvegan Associates's NVO Position: Q4 2015 in Review

Dunvegan Associates reduced its Novo Nordisk (NVO) stake by 2.1% in Q4 2015, selling an estimated $30.4K and leaving 50,454 shares worth $1.47M. The position accounts for 1.72% of the portfolio, ranked #16.

Dunvegan Associates first reported a position in NVO in Q2 2013 and has held it in 11 quarters since. The position peaked at $2.37M in Q4 2013. 549 funds tracked by Wall St. Rank hold NVO as of Q4 2015.

Dunvegan Associates held 50,454 shares of Novo Nordisk worth $1.47M as of Q4 2015.
Dunvegan Associates sold 1,100 Novo Nordisk shares in Q4 2015, an estimated $30.4K.
Novo Nordisk made up 1.72% of Dunvegan Associates's portfolio in Q4 2015, its #16 holding.
Dunvegan Associates first reported a position in Novo Nordisk in Q2 2013 and has held it in 11 quarters since.
Dunvegan Associates's Novo Nordisk position peaked at $2.37M in Q4 2013.
549 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2015.

Based on Dunvegan Associates's 13F filing for Q4 2015, filed 28 Apr 2017.